A Novel Pharmacological Therapy for Obstructive Sleep Apnea

Recruiting in Palo Alto (17 mi)

Overseen byScott A Sands, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Brigham and Women's Hospital

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests if a combination of two medications, atomoxetine and oxybutynin, can reduce the severity of sleep apnea in patients with moderate-to-severe OSA. Previous studies have shown that the combination of atomoxetine and oxybutynin can significantly reduce the severity of obstructive sleep apnea (OSA). The drugs may help keep the airway open during sleep, reducing breathing interruptions and improving sleep quality.

Research Team

Scott A Sands, PhD

Principal Investigator

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

You have been diagnosed with or are suspected to have a sleep disorder called obstructive sleep apnea (OSA).

Ages 21-70 years

Not using CPAP (>1 month)

Exclusion Criteria

You are currently taking sleep medications such as trazodone, eszopiclone, or benzodiazepines.

Respiratory disorders other than sleep disordered breathing: chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions

You have other sleep disorders such as frequent leg movements, narcolepsy, or unusual behaviors during sleep.

See 6 more